Alirocumab is a medicine that lowers "bad" LDL cholesterol and helps prevent heart attacks and strokes. It is given as an injection under the skin every two or four weeks. It works by helping the liver pull more cholesterol out of the blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Praluent (Alirocumab) for High Cholesterol (Hypercholesterolemia)?
Alirocumab, sold as Praluent, is an injectable prescription medicine that lowers LDL (low-density lipoprotein) cholesterol, the so-called bad cholesterol that builds up as plaque in artery walls. It belongs to a group of medicines called PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, named for the liver protein they block. Praluent is approved to lower the risk of heart attack, stroke, death from coronary heart disease and hospital stays for unstable angina (worsening chest pain from narrowed heart arteries) in adults at increased risk of these events. It is also approved, alongside a cholesterol-lowering diet and exercise, to lower LDL cholesterol in adults with high cholesterol, in adults and children aged 8 and older with heterozygous familial hypercholesterolemia (an inherited condition that causes very high cholesterol from birth), and in adults with homozygous familial hypercholesterolemia, a rarer and more severe inherited form. Praluent is usually added to a statin when LDL cholesterol stays too high despite the highest statin dose a person can tolerate, and it can be an option for people who cannot take statins because of muscle side effects. Repatha (evolocumab) is another PCSK9 inhibitor that works the same way.
The liver clears LDL cholesterol from the blood using LDL receptors, docking points on liver cells that capture LDL particles and pull them inside. A protein called PCSK9 attaches to these receptors and marks them for destruction, so fewer receptors are left to do the work. Alirocumab is a monoclonal antibody, a laboratory-made protein designed to latch onto one specific target. It binds PCSK9 and stops it from attaching to the receptors. More receptors survive, the liver removes more LDL from the bloodstream, and blood LDL levels fall. In a large trial of adults already taking the most statin they could tolerate, adding Praluent at its higher dose lowered LDL cholesterol by a little over half compared with placebo. Because lower LDL means less cholesterol available to build plaque, this effect is what links the medicine to fewer heart attacks and strokes.
Praluent comes as a single-use pre-filled pen that is injected under the skin of the thigh, abdomen or upper arm. Adults usually start with either a 75 mg injection every 2 weeks or a 300 mg dose every 4 weeks. The 300 mg monthly dose is given as two 150 mg injections, one right after the other, at two different sites. If LDL stays too high, the prescriber may move to 150 mg every 2 weeks, which is also the standard dose for homozygous familial hypercholesterolemia. Children with the inherited form get a dose based on body weight, given by or under the supervision of an adult. A nurse or clinician shows people how to use the pen before they inject at home. Each injection can take up to 20 seconds, and sites should be rotated, avoiding skin that is tender, bruised, red or hard. Pens are kept in the refrigerator in their carton, never frozen or shaken, and should sit at room temperature for 30 to 40 minutes before use. A pen can be kept at room temperature (up to 77°F) for up to 30 days, then must be thrown away if unused. If a dose is missed, inject it within 7 days and then return to the usual schedule. If more than 7 days have passed, people on the every-2-weeks schedule wait for their next planned dose, while people on the every-4-weeks schedule give the dose and start a new 4-week schedule from that day.
The most common side effects are reactions where the needle went in (redness, itching, swelling, pain or tenderness), flu-like symptoms and muscle aches. Injection site reactions were more frequent with the 300 mg every-4-weeks dose than with smaller doses every 2 weeks. Most of these are mild, but a reaction that keeps bothering you or does not settle is worth raising with the prescriber. Serious allergic reactions are uncommon but have occurred, including angioedema (deep swelling under the skin) and some that needed hospital care. Stop Praluent and get emergency care right away for trouble breathing or swelling of the face, lips, throat or tongue. Hives, a severe rash or severe itching also mean stopping the medicine and contacting the prescriber promptly.
Anyone who has had a serious allergic reaction to alirocumab or any ingredient in Praluent should not use it again. Praluent has no known major drug interactions listed on its US label, and it is designed to be taken together with statins and other cholesterol medicines. It is still worth giving the care team a full list of medicines and supplements. There is not enough information to know whether Praluent is safe during pregnancy. Antibodies like alirocumab cross the placenta, especially late in pregnancy, so anyone who is pregnant or planning a pregnancy should discuss whether to continue. It is not known whether alirocumab passes into breast milk, which is also a conversation to have before breastfeeding. In people with homozygous familial hypercholesterolemia whose LDL receptors barely work because of the gene changes they carry, Praluent may lower LDL very little, since it depends on those receptors to have an effect.
The cholesterol-lowering effect begins quickly, and a blood test can show the change in LDL as early as 4 weeks after starting. People on the every-4-weeks schedule usually have LDL checked just before a dose is due, because levels can drift up between injections. The result guides whether the dose needs to go up. Lower LDL does not feel like anything, so the benefit is measured in blood tests and, over years, in fewer heart attacks and strokes. In a large trial of adults who had recently had a heart attack or unstable angina and were already on strong statin therapy, about 9.5% of people taking alirocumab had a major heart or stroke event over a median of almost 3 years, compared with 11.1% on placebo. That is a meaningful reduction in risk, not a guarantee against future events. Praluent is a long-term treatment. If it is stopped, cholesterol levels rise again, so stopping should be planned with the prescriber. Keeping up with a statin if prescribed, a heart-healthy diet, exercise, and follow-up visits remains part of the plan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Praluent (Alirocumab), what you've noticed, or ask the community a question.